← Feed

u/Joehax00

3 theses · first seen Sep 4, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$SLGLr/pennystocksDDbullish
u/Joehax00 · 54d ago2 prior · awaiting results

SLGL - Sol-Gel Technologies: catalyst-driven dermatology biotech, Gorlin Phase 3 readout Q4 2026. A major 10% holder has been buying.

Sol-Gel is a binary biotech play on a Q4 2026 Phase 3 readout for SGT-610 in Gorlin syndrome with no approved therapy to prevent basal cell carcinomas. A positive result could re-rate the asset to $600m+ peak sales with patent protection to 2044, and a major 10% insider holder (Opaleye) has consistently bought through volatility, adding conviction to the thesis.

original post →
$TENXr/pennystocksDDbullish
u/Joehax00 · 70d ago2 prior · awaiting results

TENX: Tenax Therapeutics. Fully-enrolled Phase 3. Results due August. $119M cash, no debt. Another binary biotech play (kinda)

Tenax Therapeutics is a well-funded biotech play on levosimendan (LEVEL Phase 3) for PH-HFpEF, an untreated, no-competitor indication. The fully-enrolled, well-powered trial is expected to report topline results in August 2026, with 40-60% approval odds at this stage—better odds than typical biotech lottery tickets. A positive readout would likely re-rate the stock substantially as the first-to-market option in a common condition with zero approved alternatives.

Now $1.86as of Sep 11, 4:30 PM ET
original post →
$OTLKr/pennystocksDDbullish
u/Joehax00 · 89d ago2 prior · awaiting results

$OTLK - Outlook Therapeutics: one-drug biotech, FDA decision July 29, ~1 quarter of cash. Binary setup DD.

OTLK is a binary biotech betting on July 29, 2026 FDA approval of LYTENAVA, an injectable bevacizumab for wet AMD. The May 2026 appeal win established substantial efficacy evidence, leaving only labeling sign-off; approval would unlock a $8.5B market with 12 years of exclusivity as the sole approved on-label ophthalmic bevacizumab, while rejection with only one quarter of cash likely results in wipeout-level dilution or restructuring.

Now $0.66as of Sep 11, 4:30 PM ET
original post →

End of results.